ICON Awarded Best CRO at World Vaccine Congress 2017
12 April 2017 - 7:00PM
Business Wire
ICON recognised for continually setting
standards of excellence in vaccine development
ICON plc, (NASDAQ: ICLR) a global provider of drug
development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced that
it has been awarded Best Clinical Research Organisation at the
Vaccine Industry Excellence (ViE) Awards. ICON was presented with
the award at the World Vaccine Congress which took place in
Washington this week.
The ViE Awards honour individuals and organisations that
continually set standards of excellence and have made outstanding
achievements in the vaccine industry over the past 12 months. ICON
was selected by a panel of senior industry representatives from
government, academia, pharmaceutical and biotech organisations as
the best CRO according to the following criteria:
- The range of services provided in niche
and core therapeutic areas
- Methods of performance improvement or
introduction of new services
- Attention to, and quality of,
relationships with clients
- Reaching of milestones and final /
ongoing outcomes
- Building and maintaining existing and
long-term partnerships
“We are very proud to be recognised as the world’s best CRO in
vaccine development,” commented Dr. Steve Cutler, Chief Executive
Officer, ICON plc. “Over the past year, we have expanded the
capabilities of our Vaccine Centre of Excellence to provide
commercial and government clients with the services, site
relationships and geographic footprint they need to develop
vaccines for a wide range of infectious diseases and global viral
epidemics. This award is recognition of the hard work and
dedication of the ICON vaccines team and I’m delighted to see their
efforts being honoured as the industry’s best.”
ICON’s Vaccine Centre of Excellence combines in-depth vaccine
experience, extensive laboratory testing, enabling technologies and
longstanding site partnerships to help commercial and government
clients take time and cost from their vaccine development
programmes. In 2016, ICON acquired ClinicalRM, which enhanced
ICON’s capabilities in infectious diseases, vaccine development and
the response to bio-threats and global viral epidemics. ICON’s
vaccine site relationships in over 40 countries offers clients
accelerated vaccine patient recruitment capabilities, which were
further enhanced in 2015 through the acquisition of PMG Research,
an owned network of clinical research sites in 14 metropolitan
areas in the US.
Learn more about ICON’s vaccines experience at
www.iconplc.com/vaccines
About ICON plc
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 87 locations in 38 countries and has approximately
12,500 employees. Further information is available at
www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170412005406/en/
ICON Media ContactWeber ShandwickCamille FrederixTel: +44
(0)207 067 0272Email: cfrederix@webershandwick.com
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Apr 2024 to May 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From May 2023 to May 2024